• Product nameAnti-Von Willebrand Factor antibody
    See all Von Willebrand Factor primary antibodies
  • Description
    Sheep polyclonal to Von Willebrand Factor
  • SpecificityThis product has been shown to be specific by gel diffusion techniques.
  • Tested applicationsSuitable for: Double Immunodiffusion, Counter Current Immunoelectrophoresismore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human Von Willebrand Factor Antigen prepared from citrated human plasma. Greater than 95% purity by SDS-PAGE.



Our Abpromise guarantee covers the use of ab8820 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Double Immunodiffusion Use at an assay dependent dilution. 10µL antiserum vs 5µL vWF (end dilution 1mg/mL) The use of 3% PEG 6000 with 1.2% agarose in a suitable buffer (such as TBE or Tris-barbital pH >8.2) is recommended. Results can be enhanced by washing completed agarose gels in saline, drying and finally staining with a protein stain such as coomassie brilliant blue or acid blue stain.
Counter Current Immunoelectrophoresis Use at an assay dependent dilution. 20µL antiserum vs 10µL fresh plasma, wells 6mm apart, rim to rim.100v for 30 minutes


  • FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
  • Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
    Contains 4 TIL (trypsin inhibitory-like) domains.
    Contains 3 VWFA domains.
    Contains 3 VWFC domains.
    Contains 4 VWFD domains.
  • DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
  • Post-translational
    All cysteine residues are involved in intrachain or interchain disulfide bonds.
    N- and O-glycosylated.
  • Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
  • Information by UniProt
  • Database links
  • Alternative names
    • Coagulation factor VIII antibody
    • Coagulation factor VIII VWF antibody
    • F8VWF antibody
    • Factor VIII related antigen antibody
    • von Willebrand antigen 2 antibody
    • von Willebrand antigen II antibody
    • Von Willebrand disease antibody
    • VWD antibody
    • vWF antibody
    • VWF_HUMAN antibody
    see all

References for Anti-Von Willebrand Factor antibody (ab8820)

This product has been referenced in:
  • Nurkiewicz TR  et al. Pulmonary nanoparticle exposure disrupts systemic microvascular nitric oxide signaling. Toxicol Sci 110:191-203 (2009). IHC-Fr ; Rat . Read more (PubMed: 19270016) »

See 1 Publication for this product

Product Wall

Thank you for getting back to me and for gathering more information about the customer's assay.

I have conducted some search for your customer and found some products which might be suitable for this application. However, it is important to e...

Read More